Peptides for IBS & Inflammatory Bowel Disease

How peptide Targets Peptides for IBS & IBD

BPC-157 is the most extensively studied gut-healing peptide in preclinical models. Derived from a protective protein found in human gastric juice, it demonstrates acid stability that is unusual for peptides and makes oral delivery theoretically viable for GI targets. Rodent studies show BPC-157 protects against NSAID-induced gastric ulcers, accelerates anastomosis healing, restores intestinal barrier integrity, modulates inflammatory cytokine production (reducing TNF-alpha, IL-6), and influences gut motility through nitric oxide system interactions. For IBD specifically, multiple preclinical models of colitis show reduced disease severity with BPC-157 administration. For IBS, its motility-modulating and mucosal-protective effects are mechanistically relevant, though IBS is a functional disorder with different pathophysiology than the inflammatory tissue damage of IBD. No controlled human trial has evaluated BPC-157 in either IBS or IBD.

KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH) that has demonstrated potent anti-inflammatory effects in intestinal epithelial cells. In rodent colitis models, KPV reduces disease activity scores, histological inflammation, and proinflammatory cytokine levels — primarily through direct inhibition of NF-kB activation in colonocytes. A notable preclinical advance is the development of nanoparticle-formulated oral KPV that concentrates at inflamed colonic tissue, suggesting a targeted delivery approach. KPV is particularly relevant to IBD (ulcerative colitis and Crohn's disease) where mucosal inflammation drives tissue destruction. Its relevance to IBS is limited to the subset of IBS patients with demonstrable low-grade mucosal inflammation.

Larazotide acetate (AT-1001) is the most clinically advanced peptide on this list for a GI indication. It is a synthetic peptide that acts as a zonulin antagonist, tightening intestinal tight junctions and reducing paracellular permeability — the molecular basis of 'leaky gut.' Larazotide has completed Phase 2b and Phase 3 clinical trials for celiac disease, where intestinal permeability is a central disease mechanism. For IBS, the zonulin/permeability pathway is relevant to the 'leaky gut' hypothesis, though the clinical significance of mildly increased permeability in IBS is debated. Larazotide's mechanism is distinct from immunosuppression — it physically restores barrier function rather than suppressing immune activity.

LL-37 (cathelicidin) is a human antimicrobial peptide with dual relevance to GI disease. It disrupts bacterial biofilms, which are implicated in small intestinal bacterial overgrowth (SIBO) — a condition that overlaps substantially with IBS symptoms. It also modulates innate immune responses at mucosal surfaces, influencing the balance between antimicrobial defense and inflammatory tissue damage. LL-37 deficiency has been associated with increased susceptibility to GI infections and impaired mucosal healing. As a therapeutic agent, LL-37's challenge is delivery — it is degraded by GI proteases, requiring formulation strategies for gut targeting.